论文部分内容阅读
本刊讯1月8日颁布实施的《中药注册管理补充规定》抬高了中药二次研发的标准,通过提高中药改剂型和仿制品种科学合理性的要求,引导和鼓励企业从事具有自主知识的新药研发。
The Supplementary Provisions on the Registration of Traditional Chinese Medicines promulgated and implemented on January 8 raised the standards for the secondary research and development of Chinese medicines, and guided and encouraged enterprises to engage in self-knowledge by improving the scientific and rational requirements of modified dosage forms and imitation products. new medical research.